Insider Selling: Catalent, Inc. (NYSE:CTLT) CFO Sells 2,993 Shares of Stock

Catalent, Inc. (NYSE:CTLT - Get Free Report) CFO Matti Masanovich sold 2,993 shares of the stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $56.74, for a total transaction of $169,822.82. Following the sale, the chief financial officer now owns 33,871 shares in the company, valued at $1,921,840.54. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Catalent Stock Up 0.2 %

Catalent stock traded up $0.13 during mid-day trading on Wednesday, hitting $57.43. The company had a trading volume of 3,946,257 shares, compared to its average volume of 2,208,608. The stock has a market cap of $10.39 billion, a price-to-earnings ratio of -9.39, a PEG ratio of 2.36 and a beta of 1.16. The company has a quick ratio of 1.77, a current ratio of 2.51 and a debt-to-equity ratio of 1.37. Catalent, Inc. has a 1 year low of $31.80 and a 1 year high of $60.20. The business has a fifty day moving average of $55.66 and a 200 day moving average of $54.64.

Catalent (NYSE:CTLT - Get Free Report) last posted its earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.21 by ($0.36). The firm had revenue of $1.07 billion during the quarter, compared to analysts' expectations of $1.11 billion. Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. On average, sell-side analysts expect that Catalent, Inc. will post -0.17 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Catalent

Several hedge funds have recently made changes to their positions in CTLT. Lindbrook Capital LLC increased its holdings in shares of Catalent by 79.4% in the first quarter. Lindbrook Capital LLC now owns 470 shares of the company's stock valued at $27,000 after purchasing an additional 208 shares during the period. Gladius Capital Management LP purchased a new position in Catalent during the 3rd quarter worth $28,000. GAMMA Investing LLC purchased a new position in Catalent during the 4th quarter worth $33,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Catalent in the 2nd quarter worth $42,000. Finally, Rakuten Securities Inc. purchased a new stake in shares of Catalent in the fourth quarter valued at about $46,000.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on CTLT shares. Stephens reiterated an "equal weight" rating and issued a $63.50 target price on shares of Catalent in a report on Thursday, April 4th. Barclays lifted their price objective on Catalent from $47.00 to $63.00 and gave the company an "equal weight" rating in a research note on Friday, June 28th. Finally, StockNews.com initiated coverage on Catalent in a research report on Monday. They set a "sell" rating for the company. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $55.65.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.